# Study of EQU-001 for Uncontrolled Focal Onset Seizures

> **NCT05473442** · PHASE2 · TERMINATED · sponsor: **Equilibre Biopharmaceuticals B.V.** · enrollment: 27 (actual)

## Conditions studied

- Focal Onset Seizures

## Interventions

- **DRUG:** EQU-001
- **OTHER:** Matching Placebo

## Key facts

- **NCT ID:** NCT05473442
- **Lead sponsor:** Equilibre Biopharmaceuticals B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-27
- **Primary completion:** 2023-07-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** insufficient funding to complete the study
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05473442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05473442, "Study of EQU-001 for Uncontrolled Focal Onset Seizures". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05473442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*